Psychedelic-Assisted Therapy: What’s Approved, What’s Investigational, and What to Know

Psychedelic-assisted therapy has become one of the most discussed areas in mental-health research. The basic idea is to combine a carefully supervised session using a psychedelic or related substance with structured psychotherapy—preparation beforehand and “integration” afterward—to help people process difficult experiences and emotions. Early results have generated real interest, but it is important to be clear-eyed: most of these treatments are still investigational in the United States, studied mainly within clinical trials, and carry meaningful risks that require professional supervision.

This guide separates what is approved from what is investigational, summarizes the evidence conservatively, and explains why supervision matters. It is educational and is not a recommendation to use any of these substances.

What “psychedelic-assisted therapy” means

Rather than taking a medication daily, this model centers on one or a few supervised sessions. A trained therapist (often a pair) is present during the experience, which typically lasts several hours, in a prepared setting with medical monitoring. The dosing session is bracketed by psychotherapy: preparation to build trust and set intentions, and integration afterward to make sense of what came up. The therapy—not just the substance—is considered central.

Approved versus investigational

Status can change over time and can differ by state or research program, so treat the table as a general snapshot and rely on current, authoritative sources and licensed clinicians for specifics. Notably, the ketamine family is the main place where a regulated, clinic-based option currently exists; you can read more in our guide to ketamine therapy for depression.

What the evidence supports

Some early-phase studies suggest psychedelic-assisted therapy may help with conditions such as depression and post-traumatic stress disorder, sometimes with effects that appear after only a few sessions. Organizations including NIMH have funded and followed this research with cautious interest. However, the evidence is still preliminary: many trials are relatively small, blinding is difficult (participants often know whether they received an active drug), and long-term safety and real-world effectiveness are not yet well established. Reviewers such as Cochrane and professional bodies emphasize that more rigorous research is needed before firm conclusions. In short, this is a promising but unsettled field, not proven routine care.

Risks and why supervision matters

Psychedelics can cause intense psychological experiences, anxiety or panic during sessions, and changes in perception and judgment; some can raise heart rate and blood pressure. They may be unsafe for people with certain heart conditions or personal or family histories of psychosis, and they can interact with medications. There are also legal risks, since several remain controlled substances. For all these reasons, legitimate psychedelic-assisted therapy happens under medical and psychological supervision, with screening, monitoring, and follow-up. These are not do-it-yourself treatments; unsupervised or informal use can be dangerous and is not what the research describes.

Who it is being studied for—and how to access research

Trials generally focus on adults with specific conditions, such as treatment-resistant depression or PTSD, who often have not responded to standard treatments and who pass medical and psychiatric screening. If you are interested, the appropriate path today is usually a clinical trial or an approved treatment like esketamine, arranged through a qualified clinician. A psychiatrist or your primary care clinician can help you understand whether a trial or an approved option is suitable, and how your other care fits in. Our overview of therapy versus medication can help frame that broader conversation.

When to seek help

Reach out to a clinician if depression, trauma symptoms, or other mental-health concerns are interfering with your daily life, especially if they have persisted despite treatment. You do not need to wait for a novel therapy to get effective, established care now.

If you are in crisis—having thoughts of suicide or self-harm, or worried about someone who is—call or text 988 (the Suicide and Crisis Lifeline in the US) or go to your nearest emergency department right away.

Frequently asked questions

Is psychedelic-assisted therapy legal? Most psychedelics remain investigational and are controlled substances in the US; access is generally through clinical trials. Esketamine is an approved, clinic-based exception.

Does it work? Early studies are encouraging for some conditions, but evidence is preliminary and results vary; it is not proven routine care.

Can I do this at home? No. Legitimate treatment is supervised by trained clinicians with screening and monitoring; unsupervised use carries real risks.

How is it different from just taking a drug? The therapy—preparation and integration around a supervised session—is considered central, not the substance alone.

Who isn’t a candidate? People with certain heart conditions or histories of psychosis, among others, may face higher risk; screening by clinicians decides suitability.

How do I join a trial? Ask a psychiatrist or your clinician, who can point you toward reputable research programs and confirm whether you might qualify.

Explore more in our wellness guide.

Sources

• National Institute of Mental Health (NIMH) — psychedelics and mental-health research
• American Psychological Association (APA) — emerging treatments and evidence standards
• Mayo Clinic — depression and PTSD care
• Cochrane — reviews of psychedelic and related therapies